What is FeverFy?
It is a new intelligent alert system by infrared image with AI artificial intelligence assistance for early identification and prevention of infection risk. By means of thermal image of the face, in an innocuous way, ie, without any risk, without radiation, without contact, without contrast and totally safe, even for children and the elderly (most at risk group), it allows the earlier identification of suspected cases. Slows down and limits the spread of the virus before a new contagion occurs. This is made possible by combining the science of feverish anticipation in conjunction with the science of screening for epidemics.
What is it for?
Designed to protect the population, travelers, companies, factories, events, hospitals, medical centers, airports, ports, pharmacies, supply establishments and national security itself through continuous surveillance. It allows earlier measures to contain viral propagation, such as social withdrawal, isolation of infected people, quarantine of suspected cases of contagion or medical treatment when indicated. It allows health control agents to perform screening, giving immediate referral to the detached medical service and Public Health.
The goal is to measure body temperature from a distance, without contact, instead of using a thermometer in everyone's mouth or ear, which would be impractical, inappropriate and would further increase the risk of contamination. It is also necessary to use an alert system that anticipates fever and identifies the facial pattern of active infection, facilitating early mass screening and early decision making.
Is FeverFy easy to use?
Yes, it is a fully automated medical alert system. This medical system developed by Thermofy and its team of healthcare collaborators, allows sanitary control officers who work in companies, borders and hospitals to correctly use the device for automatic thermal reading and track accurately with minimal training. about the system. It makes it possible for health control agents to make a screening process, prompting the immediate referral to the detached medical service and to Public Health.
Is it expensive?
It is a Method of Collective Prevention of Respiratory Diseases whose cost in relation to any other method, such as PCR-qRT or individual clinical evaluation one by one, is negligible. The training can be done in a very short time, and for that it is enough to have a basic outpatient support structure, whether in the company, hospital, airports, ports or other institution, which already exists in our environment!
Is it a definitive exam for the diagnosis of COVID-19?
No, but it is a fast, simple, mass screening method, which can be complemented with results from laboratory tests and evaluations in medical, hospital and governmental disease control centers for definitive diagnosis confirmation.
Is there a usage protocol already?
Yes, this alert system is low cost and can be used in any environment according to international epidemiological protocols. Our system is based on the COVID 19 Coronavirus Infrared Imaging Smart-Screening Protocol and follows international ISO standards.
What is the difference with other methods, such as industrial thermography?
It is not simply a face temperature meter based on a single maximum temperature point with an alarm. In addition, both the forehead thermometer and non-contact thermography have limitations such as distance, temperature and ambient humidity, the area exactly where the device is pointing and for how long and steadily it is maintained until the reading is recorded. There is an inaccuracy because it deals with an analysis of a single dot / pixel on the face that will be altered only in the phase of higher temperature, that is, fever.
FeverFy is already a specific medical software for infection, pre-febrile stage of the pre-symptomatic person and also in the fever stage with hyperthermia, which allows, through the interpretation of thermal data using artificial intelligence, the recognition of this morbid state common in viruses .
Maximum body temperature is not always the most effective way of knowing whether a person has been infected with the new coronavirus (COVID-19). Fever occurs when the body's immune system recognizes an invader and begins releasing chemicals to increase body heat. This heat serves to make the body less hospitable to invaders and happens in spikes. But the production of inflammatory vasoactive substances, such as interleukins, and their release occurs constantly and they modify the thermal distribution of the face from the beginning, even before the manifestation of the fever itself.
What happens if I take medication to lower my fever?
The maximum body temperature can be normal. So tracking cannot be just an alarm to measure maximum or average temperature. Intelligent warning systems assess the thermal distribution in specific areas of the face, which changes when the infection is active. The inflammation / vasodilation picture can be mapped, qualified, quantified and thus trigger the alert system.
Are there other things that can increase face temperature?
Yes, medications like amphetamines, alcohol withdrawal, non-infectious diseases like silicosis and rheumatoid arthritis. This must be reported and even be documented to certify these medical conditions if the person is stopped and taken for a clinical examination after going through the smart infection tracker.
How accurate is the system?
"For the mass screening of fever, the accuracy rate of the proposed integrated artificial intelligence technique obtained a high accuracy of 96%, sensitivity of 95% and specificity of 85.6%. This is better than the method used by the researchers during the SARS- 2003 outbreak, which has 93% accuracy, 85.4% sensitivity and 95% specificity. "
Ng, E. YK. and Kee EC, “Fever Mass Screening Tool for Infectious Diseases Outbreak: Integrated artificial intelligence with bio-statistical approach in thermogram analysis”, Medical Infrared Imaging, Biomedical Engineering Handbook, ISBN-0-8493-9027-3, CRC Press, 2008, FL, USA, Editor: Nicholas Diakides and Joseph D. Bronzino, Chp. 16, pp. 1-19.